The aim of this project is to identify, characterize and investigate a large number of cancer (sub)types for the expression levels and profile of the FRα. High-throughput tissue microarray screening for FRα expression will be performed at the University Hospital Zurich using state-of the art methodologies. Information about the FRα expression on a variety of tumor types will be essential in view of our goal to develop FR-targeted radionuclide therapy. At the Center for Radiopharmaceutical Sciences at Paul Scherrer Institute (Villigen-PSI), the design of FRα-targeting folate radioconjugates will be optimized to reduce undesired kidney retention and allow their use for therapeutic purposes. The project should form the basis for a new theragnostic concept with the long-term goal to provide a valid approach for personalized precision medicine in oncology.